drugset / Trial / NCT00752505

A Study To Assess Esreboxetine's Effect On Concentration, Memory, Decision Making And Problem Solving In Patients With Fibromyalgia.

NCT00752505

Phase 2 Completed 89 enrolled Pfizer
RandomizedCrossoverQuadruple-blindTreatment

Summary

The study is designed to assess if esreboxetine can improve the cognitive function of patients with fibromyalgia. Cognitive function is defined as the ability to concentrate, remember things and make decisions or problem solve. The study is also designed to assess if there is a difference in cognitive function between fibromyalgia patients and matched control subjects.

Timeline

Start
2008-08
Primary completion
2009-06
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject [S,S]-Reboxetine Unknown 4 mg
Subject [S,S]-Reboxetine Unknown 8 mg

Indications